selectivity is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-10-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
=== 2011–2017: The Only Way Is Essex, I'm a Celebrity...Get Me Out of Here! and Celebrity Big Brother === In January 2011, Julie Childs, mother of Collins' friend Amy, suggested to producers of the ITV2 reality series The Only Way Is Essex that Collins would be an appropriate subject. They visited Collins' house and subsequently filmed her and her friends for two weeks. After returning to work as a car sales executive for a week, she was cast in the programme and began appearing in The Only Way Is Essex from its second series beginning in March 2011. Her first scene saw her attempting to sell a car to Kirk Norcross and taking him for a test drive. Collins ultimately quit her job to appear on the programme full time, and was paid £50 a day for her early appearances on the show, which she described as a "massive risk". Her mother Joan joined the programme during the fifth series in April 2012. From September 2011 until March 2013, Collins wrote a regular column in the tabloid magazine Closer. In April 2013, she released her debut autobiography Basically...: My Life as a Real Essex Girl, which became a bestseller in its first week of release. In January 2014, Collins took part in the second series of the ITV diving competition Splash!. During training, Collins suffered severe bruising and admitted she had to overcome a fear of water. She became the third celebrity to be eliminated after losing the splash-off to Michaela Strachan in the first heat. In November 2014, she took part in the fourteenth series of I'm a Celebrity...Get Me Out of Here! on ITV.
=== Synthesis === A chemical synthesis of mirtazapine has been published. The first step of synthesis is a condensation reaction between 2-chloro-3-cyanopyridine (1) and 1-methyl-3-phenylpiperazine (2) to give cyano compound 3. Hydrolysis of the cyanide group to the corresponding carboxylic acid (4), reduction to the alcohol (5) allows for mirtazapine (6) to be synthesised via an acid mediated cyclisation.
==== Tax deduction for executive compensation ==== Public companies are not allowed to take a tax deduction for compensation paid to certain executives that exceeds $1 million per year. Effective tax years beginning after December 31, 2026, the compensation paid to the five most highly compensated executives is expanded to all members of a covered corporation's controlled group and affiliated service group. The tax deductible portion of compensation is allocated to each control group member based on the pro-rata portion of the compensation paid by that member.
Sources: en.wikipedia.org
== Substrates == So far, more than 150 proteins have been identified to be targets for CK1-mediated phosphorylation, at least in vitro. Phosphorylation of numerous substrates is enabled due to the existence of several consensus motifs, which can be recognized by CK1 isoforms.
=== France === France was obligated to join Russia due to their 1893 military alliance. French bankers did have financial interests in Russia, especially in railroads. However, France had no territorial ambitions in Manchuria, as its sphere of influence was in southern China (see Sino-French War). The French actually had cordial relations with the Japanese: French military advisors had been sent to train the Imperial Japanese Army since the expedition in 1867 and a number of Japanese ships were built in French shipyards. However, France did not wish to be diplomatically isolated, as she had been previously during Bismarck’s diplomatic quarantine of revanchist France after the Franco-Prussian War, especially given the growing power of Germany.
Dextran drug delivery systems involve the use of the natural glucose polymer dextran in applications as a prodrug, nanoparticle, microsphere, micelle, and hydrogel drug carrier in the field of targeted and controlled drug delivery. According to several in vitro and animal research studies, dextran carriers reduce off-site toxicity and improve local drug concentration at the target tissue site. This technology has significant implications as a potential strategy for delivering therapeutics to treat cancer, cardiovascular diseases, pulmonary diseases, bone diseases, liver diseases, colonic diseases, infections, and HIV. Although there are many FDA approved natural polymeric-based drug carriers available for clinical use, dextran has failed to obtain any clinical applications. Research must address several challenges and obstacles associated with dextran before it can become a viable, clinically approved drug delivery strategy.
Sources: en.wikipedia.org
==== Distribution ==== The brain tissue distribution of muscimol in rats has been studied. Muscimol rapidly enters and unevenly distributes in rat brain, especially in the substantia nigra, colliculi, and hypothalamus. Muscimol crosses the blood–brain barrier and hence is centrally active. This has been said to likely be mediated by active transport via the high-affinity GABA uptake system and other amino acid transporters. Although muscimol crosses the blood–brain barrier, it does so relatively poorly and far less readily than gaboxadol.
Further work by Crick and co-workers showed that the genetic code was based on non-overlapping triplets of bases, called codons, allowing Har Gobind Khorana, Robert W. Holley, and Marshall Warren Nirenberg to decipher the genetic code. These findings represent the birth of molecular biology.
Mazda's automotive plans for the early sixties consisted of growing alongside the Japanese economy. To achieve this goal, they began by building an extremely affordable kei car, the R360 in 1960, planning on introducing gradually larger and pricier cars as the Japanese customers became able to afford them. As a preview, testing the waters, a larger "Mazda 700" prototype was shown at the eighth Tokyo Motor Show in 1961, and formed the basis for the upcoming Mazda Familia. Meanwhile, the four door version of the R360 was introduced as the Mazda Carol, which appeared in 1962, and discontinued in 1964. The first production Familia, styled by a young Giorgetto Giugiaro while working at Carrozzeria Bertone, appeared in October 1963. In line with Mazda's policy of only gradually approaching the production of private cars (a luxury in Japan at the time), the first Familia was initially only available as a commercial two-door wagon called the Familia van. The van was joined in April 1964 by a plusher Familia wagon, in October by a four-door saloon, and in November by a two-door saloon. The "flat deck" design of the saloon versions was reportedly inspired by the Chevrolet Corvair. Private car versions received foglights in the grille as well as more chrome trim. The Familia was sold in other markets as the 800. The Familia was introduced to the Japanese market in time for the 1964 Summer Olympics which began in October. The cars used a 782 cc, "SA" four-stroke aluminum straight-four engine, also known as the "white engine".
== Properties == nanoCLAMPs are the first antibody mimetics described to be polyol-responsive, meaning they release their targets upon exposure to a non-chaotropic salt and a polyol, such as propylene glycol. This property has been shown to be useful for purifying functional proteins and protein complexes by affinity purification. nanoCLAMPs are easily produced in the cytoplasm of E. coli, with typical yields in the range of 50 to 300 mg/L culture. Because nanoCLAMPs are devoid of cysteines, an engineered C-terminal cysteine can be used for site-directed conjugation of entities like fluorophores or resins using thiol-chemistry.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.